PJY06 - Detection of clinically relevant prostate cancer from multi-parametric 3Tesla MRI scans using artificial intelligence

Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): A. Aydin, C. Kahir, M. Patel, C. Allen, P. Dasgupta
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

This study aims to analyze the prognostic importance of serum PSA response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer. METHODS: Thirty consecutive patients who received Lu-177 PSMA treatment for their castration-resistant prostate carcinoma were included. All the patients had undergone Ga-68 PSMA PET/CT scanning before Lu-177 PSMA therapy, which revealed multiple metastases. Patients were treated with a fixed dose (180 mCi) of Lu-177 PSMA at six to eight weeks intervals. Prostate specific antigen (PSA) response ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
An automated bone scan algorithm has shown its value in determining the response...Read more on AuntMinnie.comRelated Reading: Rethinking Ga-68 PSMA-11 PET/CT for bone metastases NaF-PET/CT rarely finds prostate cancer bone metastases Bone scan software predicts prostate cancer survival Hybrid modalities disappoint in bone metastases accuracy ASTRO updates guidelines on painful bone metastases
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Abstract13N-Ammonia (13N-NH3) is widely used positron emission tomography/computed tomography (PET/CT) radiotracer for the measurement of myocardial blood perfusion; the possible role of13N-NH3 PET or PET/CT in oncological disease is not yet clear. Aim of this review is to evaluate the diagnostic performances of13N-NH3 PET in this field. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Embase databases was conducted including articles up to June 2019. Eighteen articles were finally included in the review. From the analyses of the selected studies, the following main findings could be drawn: (1)...
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
Tansel Cakir, Selcuk Guven, Bahar Muezzinoglu, Cengiz Erol, Mustafa Yucel Boz, Tamer AtaseverUrology Annals 2019 11(4):439-442 While 68Gallium prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA) has demonstrated increasing utility in the evaluation of prostatic carcinoma, it is essential to be aware of false-negative findings. Further subtype analyses of prostate cancer will be helpful in the understanding of the underlying reasons. We herein present a high-grade prostate adenocarcinoma, with metastatic lesions showing high 18F-labeled fluoro-2-deoxyglucose uptake instead of 68Ga-PSMA.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
ConclusionsThis retrospective study suggests that, after a median follow-up of 3  months under enzalutamide or abiraterone, PSMA expression changes on PET/CT are strongly associated with response to treatment. Prospective studies are needed to better understand PSMA expression dynamics following the start of enzalutamide and abiraterone, along with the role of PSMA PET/CT in re sponse assessment.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
We present images of Lu-DOTATATE scan and Ga-DOTATATE PET/CT scan conducted on a 65-year-old man with prostate cancer with neuroendocrine differentiation, whose disease progressed despite conventional treatment and Lu-PSMA radioligand therapy; however, an extraordinary radiographic tumor remission, biochemical response, and improvement of clinical symptoms were observed after the patient underwent Lu-DOTATATE peptide receptor radionuclide therapy. PMID: 31584494 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
This study investigates and optimizes the BAD map approach for sCT quality assurance with a large patient CT and MRI dataset. 3D T2-weighted MRI and full density CT images of 54 patients were used to create BAD maps with different tissue class combinations. Mean Hounsfield units (HU) of Fat (F: below −30 HU), the entire Tissue [T: excluding bone (B)], and Muscle (M: excluding bone and fat) were derived from the CT scans. CT based BAD maps (BADBT,CT and BADBMF,CT) and a conventional bone and water bulk-density method (BADBW,CT) were compared to full CT calculations with bone assignments to 366 HU (measured) and 288 HU...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsImmunotherapy with primary DC subsets induced functional antigen-specific T cells. The presence of functional antigen-specific T cells correlated with longer rPFS.Clinical trial identificationNCT02692976.Legal entity responsible for the studyJolanda de Vries and Winald Gerritsen.FundingThis work was supported by Stichting Afweer Tegen Kanker, Dr. Paul A.J. Speth Stichting and H2020 EU grant PROCROP (grant No 635122). Carl G. Figdor received ERC Adv Grant PATHFINDER (269019) and the NWO Spinoza grant. I. Jolanda M. de Vries received NWO-Vici grant (918.14.655).DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThere are currently no good indicators of which patients with cancer will respond or not to immunotherapy. Novel computational analysis of computed tomography scans (CT) (i.e. radiomics) provides information about the tumour-infiltrating CD8 and predict response to immunotherapy. We aim to validate in an external cohort the VHIO CT-radiomics signature and to develop a combined radiomics-clinical signature that predicts the response to immune checkpoint inhibitors in patients with advanced solid tumours.MethodsThe VHIO CT-radiomics signature was developed in a population of 115 consecutive patients treated...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Lesion-targeted TULSA demonstrates accurate and safe ablation of PCa. A significant increase of post-TULSA non-perfused-volume was observed during 3 weeks follow-up concordant with necrosis on histology. TULSA achieved coagulation necrosis of all targeted tissues. A limitation of this treat-and-resect-study-design was conservative treatment near NVB in patients scheduled for RALP. PMID: 31556779 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
More News: Cancer | Cancer & Oncology | PET Scan | Prostate Cancer | Urology & Nephrology